|
|
|
| The Relationship Between XRCC1 TYMS MTHFR Gene Polymorphisms and the Efficacy of Adjuvant Chemotherapy After Colon Cancer Surgery |
| ZHAO Shuai, CHEN Jing, YAN Haiyang, et al |
| The First Hospital of Hebei Medical University, Hebei Shijiazhuang 050031, China |
|
|
|
|
Abstract Objective: To investigate and analyse the efficacy of adjuvant chemotherapy with FOLFOX4 after surgery for stage II and III colon cancer, and to analyse the relationship between X ray repair cross complementary gene I (XRCC1), TYMS, methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and efficacy, with the aim of finding and analysing the predictors of adjuvant chemotherapy. Methods: The clinical data of 104 patients who received 6 cycles of FOLFOX4 adjuvant chemotherapy after the end of surgical treatment admitted to our hospital from May 2018 to January 2020 were retrospectively analyzed, and the 2-year disease-free survival rate was judged at follow-up after treatment and used as an efficacy evaluation criterion. DNA was extracted from tumour tissue specimens of all patients, and XRCC1, TYMS and MTHFR genotypes were tested. A chi-square test was used to compare the recurrence rates between genotypes, followed by a COX regression model to explore factors that might have an impact on the efficacy. Results: The genotype distribution of XRCC1, TYMS and MTHFR was dominated by G/A genotype, 2R/3R genotype and T/C genotype respectively, which were significantly higher than the other genotypes, and the difference was statistically significant (P<0.05). The difference was statistically significant (P<0.05). The XRCC1 gene polymorphism had a direct effect on the disease-free survival rate at 2 years after FOLFOX4 adjuvant chemotherapy for colon cancer (P<0.05). The results of the univariate analysis of the COX model showed that TNM stage, intestinal wall infiltration, XRCC1 and adjuvant chemotherapy with FOLFOX4 after surgery for colon cancer were correlated (P<0.05). Conclusion: The XRCC1 gene polymorphism has a direct correlation with disease free survival at 2 years after FOLFOX4 adjuvant chemotherapy for colon cancer.Detection of XRCC1 polymorphism can be used as a reliable predictor of the efficacy of adjuvant chemotherapy with FOLFOX4 after surgery for stage II and III colon cancer.
|
|
|
|
|
|
[1] 韦金磊,张森.Ⅲ期结肠癌老年患者根治术的疗效相关因素及生存分析[J].中国临床研究,2019,32(2):179~183.
[2] 覃军,王耀明,郑广才,等.DNA错配修复蛋白缺失与Ⅱ、Ⅲ期结肠癌根治术后复发转移及疗效的关系[J].新疆医科大学学报,2020,43(5):607~610.
[3] 中华人民共和国卫生和计划生育委员会医政医管局.中国结直肠癌诊疗规范(2017年版)[J].中华外科杂志,2018,12(1):3~23.
[4] 孟丽,李海迎,马兆龙,等.GSTP1基因多态性与局部晚期食管癌同步放化疗疗效及疗效相关性研究[J].中华肿瘤防治杂志,2020,27(12):969~973.
[5] 杨建新.结肠癌行根治术后辅助化疗的效果及影响疗效的因素分析[J].现代诊断与治疗,2019,30(3):455~456.
[6] 苟苗苗,张勇,千年松,等.DPYD、ABCB1、GSTP1、ERCC1基因多态性与晚期结肠癌临床特征、不良反应、疗效的关系[J/CD].中华结直肠癌疾病电子杂志,2019,8(2):125~130.
[7] 李荣振,梅家转,夏云展,等.真实世界中R0切除术后结直肠癌患者接受卡培他滨为基础辅助化疗的疗效影响因素及安全性探讨[J].中国临床药理学与治疗学,2019,24(6):704~711.
[8] 何光照,刘茜,李小倩,等.氟尿嘧啶类药物个体化用药研究进展[J].中国医院药学杂志,2018,38(6):679~683.
[9] Paul P,Deka H,Malakar AK,et al.Nasopharyngeal carcinoma:understanding its molecular biology at a fine scale[J].Eur Cancer Prev,2018,27(1):33~41.
[10] 张杰,李昌海,李林子,等.DPYD、GSTP1、MTHFR基因多态性对5-FU类基础化疗结直肠癌患者疗效的影响[J].山东医药,2020,60(0):9~10.
[11] 陈唯唯,王文玲,王刚,等.X射线修复交叉互补基因1多态性与直肠癌新辅助放化疗疗效的前瞻性队列研究[J].中华放射医学与防护杂志,2020,40(10):740~745. |
|
|
|
2022, Vol. 28 
